[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

O’Hara et al., 2020 - Google Patents

LRRK2 and α-synuclein: distinct or synergistic players in Parkinson's disease?

O’Hara et al., 2020

View HTML
Document ID
16819080512472215511
Author
O’Hara D
Pawar G
Kalia S
Kalia L
Publication year
Publication venue
Frontiers in neuroscience

External Links

Snippet

Parkinson's disease (PD) is the most common neurodegenerative movement disorder, characterized by prominent degeneration of dopaminergic neurons in the substantia nigra and aggregation of the protein α-synuclein within intraneuronal inclusions known as Lewy …
Continue reading at www.frontiersin.org (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Similar Documents

Publication Publication Date Title
O’Hara et al. LRRK2 and α-synuclein: distinct or synergistic players in Parkinson’s disease?
Lehtonen et al. Dysfunction of cellular proteostasis in Parkinson’s disease
Bridi et al. Mechanisms of α-synuclein induced synaptopathy in Parkinson's disease
Ghiglieri et al. Alpha-synuclein: from early synaptic dysfunction to neurodegeneration
Stroo et al. Cellular regulation of amyloid formation in aging and disease
Li et al. PARK genes link mitochondrial dysfunction and alpha-synuclein pathology in sporadic Parkinson’s disease
Abeliovich et al. Parkinsonism genes: culprits and clues
Usmani et al. The cell biology of LRRK2 in Parkinson's disease
Snead et al. Alpha-synuclein function and dysfunction on cellular membranes
Dagda et al. Beyond the mitochondrion: cytosolic PINK 1 remodels dendrites through Protein Kinase A
Burlot et al. Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology
Wales et al. Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration
Tenreiro et al. Protein phosphorylation in neurodegeneration: friend or foe?
Guardia‐Laguarta et al. A new role for α‐synuclein in Parkinson's disease: Alteration of ER–mitochondrial communication
Picconi et al. Synaptic dysfunction in Parkinson’s disease
Gandhi et al. Leucine‐rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease
Cresto et al. The unlikely partnership between LRRK 2 and α‐synuclein in Parkinson's disease
Guerra de Souza et al. SUMO‐regulated mitochondrial function in Parkinson's disease
Gu et al. TDP-43 suppresses tau expression via promoting its mRNA instability
Greggio et al. Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease?
Horowitz et al. Gene–environment interactions in Parkinson's disease: the importance of animal modeling
Lee et al. Genetic factors involved in the pathogenesis of Parkinson's disease
Strong et al. Alterations in Tau Metabolism in ALS and ALS-FTSD
Wang et al. Delta-secretase (AEP) mediates tau-splicing imbalance and accelerates cognitive decline in tauopathies
Singh et al. Iron in neurodegenerative disorders of protein misfolding: a case of prion disorders and Parkinson's disease